The COVID-19 vaccine continues to save lives, proving the vaccination strategy paid off and was a worthwhile national ...

The first quarter of 2025 was a tough one. The S&P 500 lost 4.6%, and the Nasdaq Composite lost 10.4%. Following the trend, ...

The US Food and Drug Administration has delayed granting full approval of Novavax’s Covid-19 vaccine despite it being on ...

The rivalry between Moderna and Pfizer/BioNTech in commercialising their COVID-19 vaccines has now spilled over into the courts, in the form of a patent infringement lawsuit.

Shares of vaccine-maker Moderna MRNA closed at $34.71 on Monday, close to their 52-week low of $29.25. Moderna is facing several headwinds, including the declining COVID-19 vaccine and the soft ...

Five years ago, volunteers rolled up their sleeves in the first clinical trial of a vaccine against COVID-19, as the new pandemic surged around them. By a year later, 66 million American adults had ...

Moderna stock has dropped more than 70% over the past year. The company’s coronavirus vaccine no longer is driving outsized growth -- and Moderna is still in the process of ushering in newer ...

March 5, 2025 Pfizer convinces US Patent Office to cancel two Moderna COVID-19 vaccine patents Pfizer and BioNTech won a round in their legal battle with Moderna over COVID-19 vaccine patents on ...

The cause for his optimism was the fact that more than 182 million Americans had received at least one shot of the new COVID-19 vaccines, including nearly 90 percent of seniors and 70 percent of ...